CVAC News and Press, CureVac N.V. From 07/14/23

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 14, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. Igor Splawski, CureVac's Chief...

2023-07-13 11:54:05 ET CureVac ( NASDAQ: CVAC ) announced Thursday it widened the legal scope of its patent litigation, with Pfizer ( PFE ) and BioNTech ( BNTX ) bringing additional claims of patent infringement in a German court to challenge the companies' updated COVID vac...

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eight Tenth patent add...

2023-06-23 12:35:00 ET Shares of CureVac (NASDAQ: CVAC) were up by 14.3% for the week as of Friday morning, after having been up by as much as 16%, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stock closed last week ...

2023-06-20 18:29:00 ET A successful cancer drug or vaccine is the holy grail of biotech companies. On news that its cancer-vaccine candidate had reached an important new stage of development, Germany-based CureVac (NASDAQ: CVAC) saw its share price pop by 12% on Tuesday. That compar...

Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma Study designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical resection and radiotherapy First study ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 20, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Michael Brosnan as a...

2023-06-07 07:07:57 ET Promosome LLC became the latest to stake a claim to the groundbreaking messenger-RNA-based vaccine technology when the New York-based biotech filed a lawsuit against Pfizer ( PFE ), BioNTech ( BNTX ), and Moderna ( NASDAQ: MRNA ) on Tuesday in a Califo...

Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement counterclaim in U.S. patent litigation with Pfizer/BioNTech; case filed under nine CureVac ...

2023-05-23 14:10:22 ET Despite sharp year-to-date declines, shares of leading COVID-19 vaccine developers spiked on Tuesday amid fears that China is facing a new wave of coronavirus infections. Respiratory disease specialist Zhong Nanshan warned that the country would see as many as 65M...